Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4751164
Max Phase: Preclinical
Molecular Formula: C28H30ClN9O5S
Molecular Weight: 640.13
Molecule Type: Unknown
Associated Items:
ID: ALA4751164
Max Phase: Preclinical
Molecular Formula: C28H30ClN9O5S
Molecular Weight: 640.13
Molecule Type: Unknown
Associated Items:
Canonical SMILES: C=CC(=O)NCCNc1c(NCc2ccc(Nc3ncc(Cl)c(NCc4cccnc4N(C)S(C)(=O)=O)n3)cc2)c(=O)c1=O
Standard InChI: InChI=1S/C28H30ClN9O5S/c1-4-21(39)30-12-13-31-22-23(25(41)24(22)40)33-14-17-7-9-19(10-8-17)36-28-35-16-20(29)26(37-28)34-15-18-6-5-11-32-27(18)38(2)44(3,42)43/h4-11,16,31,33H,1,12-15H2,2-3H3,(H,30,39)(H2,34,35,36,37)
Standard InChI Key: COBUBKXVXDHVBG-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 640.13 | Molecular Weight (Monoisotopic): 639.1779 | AlogP: 2.20 | #Rotatable Bonds: 15 |
Polar Surface Area: 187.41 | Molecular Species: NEUTRAL | HBA: 12 | HBD: 5 |
#RO5 Violations: 2 | HBA (Lipinski): 14 | HBD (Lipinski): 5 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 13.49 | CX Basic pKa: 4.54 | CX LogP: 1.42 | CX LogD: 1.42 |
Aromatic Rings: 4 | Heavy Atoms: 44 | QED Weighted: 0.07 | Np Likeness Score: -1.23 |
1. Li B,Li Y,Tomkiewicz-Raulet C,Dao P,Lietha D,Yen-Pon E,Du Z,Coumoul X,Garbay C,Etheve-Quelquejeu M,Chen H. (2020) Design, Synthesis, and Biological Evaluation of Covalent Inhibitors of Focal Adhesion Kinase (FAK) against Human Malignant Glioblastoma., 63 (21): [PMID:33119295] [10.1021/acs.jmedchem.0c01059] |
Source(1):